Skip to main navigation Skip to search Skip to main content

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

  • EORTC Melanoma Group

Research output: Contribution to journal › Article › peer-review

65   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry